SynthesisTransplant international : official journal of the European Society for Organ Transplantation
Donor-Transmitted Cancer in Orthotopic Solid Organ Transplant Recipients: A Systematic Review.
Synthesis in Transplant international : official journal of the European Society for Organ Transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Donor-Transmitted Cancer in Orthotopic Solid Organ Transplant Recipients: A Systematic Review.Transplant international : official journal of the European Society for Organ TransplantationPooled it
- Targeting tumor dormancy: the next frontier in gastrointestinal stromal tumor therapy.Neoplasia (New York, N.Y.) · 2026Review
- The Value of Chest and Abdominal CT Scans in Deceased Organ Donor Screening: A Prospective Nationwide Cohort Study.Transplantation direct · 2025Article
- Utilization and outcomes of lung transplant from donors with cancer: a UNOS study.Journal of thoracic disease · 2025Article
- Analysis of Unused Organ Donors in the Netherlands: Older Donor Age Associated With Higher Risk of Non-Utilization.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Donors With Previous Malignancy: When Is It Safe to Proceed With Organ Transplantation?Transplant international : official journal of the European Society for Organ Transplantation · 2025Review
- Genitourinary tumors and liver transplantation: A comprehensive review.World journal of transplantation · 2024Review
- Elucidating the nexus between onco-immunology and kidney transplantation: An insight from precision medicine perspective.Heliyon · 2024Review
- Dormancy in Breast Cancer.Cold Spring Harbor perspectives in medicine · 2023Review
- Donors With a Prior History of Cancer: Factors of Non-Utilization of Kidneys for Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Vigilance Data in Organ Donation and Solid Organ Transplantation in Germany: Six Years of Experience 2016-2022.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Excellence in Organ Utilisation-A Quantitative and Qualitative Evidence Base for a New Approach in the UK.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Spontaneous regression of a metastatic carcinoma transmitted by a kidney graft.Exploration of targeted anti-tumor therapy · 2023Article
- URGENT LIVER RETRANSPLANTATION DUE TO TRANSMISSION OF INTRAHEPATIC CHOLANGIOCARCINOMA BY DONOR: THE FIRST REPORT IN THE LITERATURE.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2023Article
- Lungs From Donors ≥70 Years of Age for Transplantation-Do Long-Term Outcomes Justify Their Use?Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Donor-transmitted cancer (DTC) has major implications for the affected patient as well as other recipients of organs from the same donor. Unlike heterotopic transplant recipients, there may be limited treatment options for orthotopic transplant recipients with DTC. We systematically reviewed the evidence on DTC in orthotopic solid organ transplant recipients (SOTRs). We searched MEDLINE, EMBASE, PubMed, Scopus, and Web of Science in January 2020. We included cases where the outcome was reported and excluded donor-derived cancers. We assessed study quality using published checklists. Our domains of interest were presentation, time to diagnosis, cancer extent, management, and survival. There were 73 DTC cases in liver (n = 51), heart (n = 10), lung (n = 10) and multi-organ (n = 2) recipients from 58 publications. Study quality was variable. Median time to diagnosis was 8 months; 42% were widespread at diagnosis. Of 13 cases that underwent re-transplantation, three tumours recurred. Mortality was 75%; median survival 7 months. Survival was worst in transmitted melanoma and central nervous system tumours. The prognosis of DTC in orthotopic SOTRs is poor. Although re-transplantation offers the best chance of cure, some tumours still recur. Publication bias and clinical heterogeneity limit the available evidence. From our findings, we suggest refinements to clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.